Company intelligence / Profile preview

Maoxiang Group

Tianjin Shi, Tianjin Shi, Chinabmsscience.com ↗

Ownership: Private
Development stage: Other

Overview

Maoxiang Group refers to two related pharmaceutical companies in China—one formerly based in Tianjin and now dissolved, another active in Jilin province. Both have focused on developing small molecule drugs targeting infectious and metabolic/nervous system disorders. Their pipelines include generics such as cephalexin and rifampin with approved status for indications like acute bacterial sinusitis and leprosy respectively. No proprietary platform technologies or novel biologics are reported; their business centers around established antibiotics.

Therapeutic areas: PulmonologyEndocrinologyHematologyOtherNeurologyInfectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Beyond the preview

Go deeper on Maoxiang Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maoxiang Group.

Explore the full profile